Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
The aim of this study is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventional studies.
Checked against the public recordLast updated Feb 10, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- University of Oklahoma
- Interventions being studied
- Biological: Immunotherapy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * above age 18, * histologically and cytologically confirmed NSCLC, melanoma, head and neck squamous cell carcinoma, gastrointestinal cancers,, renal cell carcinoma, or any other solid tumors where immune checkpoint therapy has been used * received immunotherapy as part of their treatment * Self-identified American Indian in ethnicity * Patients at the Stephenson Cancer Center between 2015 to 2021 Exclusion Criteria: * patients who did not receive immune checkpoint inhibitor therapy
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Arizona Cancer Center at the Unvieristy of ArizonaTucson, Arizona
- University of New Mexico Comprehensive Cancer CenterAlbuquerque, New Mexico
- Stephenson Cancer CenterOklahoma City, Oklahoma
- Monument Health Cancer Care InstituteRapid City, South Dakota
- Avera Cancer InstituteSioux Falls, South Dakota
- Huntsman Cancer Institute at the University of UtahSalt Lake City, Utah
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 10, 2026. Always confirm current availability with the study team.